5-Amino-1MQ NNMT Inhibitor Research Guide 2026 — Molecular Profile, NAD+/SAM Mechanism & Verification

5-Amino-1MQ is not a peptide. It is a small-molecule quinolinium — a single aromatic ring system rather than an amino-acid chain — and that distinction matters for anyone sourcing it, because it changes the analytical methods, the salt-form questions, and the literature it belongs to. What makes it a heavily studied research compound is its target: 5-amino-1MQ is a selective, cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), an intracellular enzyme that sits at the intersection of two of the most-studied pathways in metabolic and longevity research — the NAD+ salvage pathway and the SAM (S-adenosylmethionine) methylation cycle. For groups modeling adipocyte energetics, NAD+ economy, or methyl-donor flux, an inhibitor that dials NNMT activity down without hitting related methyltransferases is a valuable probe.

This guide is written for qualified laboratory researchers sourcing 5-amino-1MQ as a research compound. It covers the molecular profile, the mechanism at the enzyme and pathway level as described in the published literature, representative preclinical data, real citations verifiable through PubMed and PubMed Central, in-vitro research applications, how to evaluate the analytical documentation that should accompany a compound of this class, and the current U.S. regulatory context as of July 2026.

For in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use.

Section 1 — Molecular Profile

5-Amino-1MQ is the common name for 5-amino-1-methylquinolinium: a quinolinium scaffold (a bicyclic aromatic ring with a positively charged, methylated ring nitrogen) carrying a primary amino group at the 5-position. That permanent positive charge on the ring nitrogen is the single most important structural fact about the molecule, because it defines both how the compound behaves analytically and how it is supplied.

• Compound name: 5-Amino-1MQ
• Chemical name: 5-amino-1-methylquinolinium
• Active cation: C₁₀H₁₁N₂⁺ (≈ 159.2 g/mol)
• Common salt form: iodide, C₁₀H₁₁IN₂ (≈ 286.1 g/mol)
• CAS number: 42464-96-0 (associated with the 5-amino-1-methylquinolinium designation; note that CAS assignment and reported mass vary by salt form)
• Class: small-molecule quinolinium; substrate-competitive NNMT inhibitor
• Appearance: typically supplied as a lyophilized or crystalline powder; the permanently charged cation is water-soluble and reconstituted in aqueous buffer for in-vitro work

Two sourcing details follow directly from the structure. First, because the active species is a permanently charged cation, it is always paired with a counter-ion, and the counter-ion is not cosmetic. A quantity stated in milligrams of “5-amino-1MQ” means something different depending on whether the material is the free cation reference, the iodide salt, the chloride salt, or another form — the counter-ion contributes mass, so net cation content per milligram differs. A complete certificate should state the salt form explicitly.

Second, this is a small molecule of roughly 159 Da (cation), not a multi-hundred-dalton peptide. On mass spectrometry the identity signature is a clean cation signal near 159 m/z rather than the multiply-charged envelope a peptide produces. This is why 5-amino-1MQ should not be evaluated with peptide-style expectations: there is no sequence to confirm, and the relevant impurity questions concern synthetic byproducts, residual solvents, and counter-ion identity rather than deletion sequences.

Section 2 — Mechanism (Pathway Language)

5-Amino-1MQ is studied as a substrate-competitive inhibitor of nicotinamide N-methyltransferase. The published mechanistic literature describes it strictly at the level of enzyme kinetics and metabolite pools — not at the level of any clinical endpoint.

The enzyme it targets. NNMT catalyzes the transfer of a methyl group from SAM to nicotinamide (the amide form of vitamin B3), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). That single reaction touches two pathways at once. Nicotinamide is a precursor the cell uses to regenerate NAD+ through the salvage pathway; methylating it diverts nicotinamide toward excretion as 1-MNA. And because the reaction consumes SAM, high NNMT activity is described in the literature as a “methyl sink” that draws down the cellular methyl-donor pool. NNMT inhibition is therefore studied as a way to raise both NAD+ and SAM availability in a preparation simultaneously.

Substrate-competitive inhibition. 5-Amino-1MQ occupies the nicotinamide-binding region of NNMT, competing with the natural substrate. The characterizing work reported that the primary-amine quinolinium scaffold combined potency at NNMT with high membrane permeability — important for an intracellular enzyme, since a probe must cross the cell membrane to reach its target.

Selectivity. The published characterization emphasized that 5-amino-1MQ did not meaningfully inhibit other SAM-dependent methyltransferases tested, nor enzymes of the NAD+ salvage pathway. That selectivity is what makes it useful as a research tool: an effect observed after treatment can be attributed to NNMT inhibition rather than to broad methyltransferase disruption.

Downstream metabolite shifts. In cultured adipocytes, NNMT inhibition was reported to lower intracellular 1-MNA while raising NAD+ and SAM — the metabolite fingerprint predicted by blocking the enzyme. NAD+ and SAM in turn feed NAD+-dependent signaling (including sirtuin activity) and methylation reactions, which is the pathway logic connecting NNMT to the broader metabolic literature.

This article describes 5-amino-1MQ strictly at the enzyme-kinetic and metabolite-pool level. It is studied for its substrate-competitive inhibition of NNMT and the associated shifts in NAD+, SAM, and 1-MNA in controlled systems; no human outcome, therapeutic, or physiological benefit is claimed or implied.

Section 3 — Preclinical Research Data

The 5-amino-1MQ literature is built on cell-free enzyme assays, adipocyte cell-culture work, and rodent models. Every result below is a preclinical measurement in an experimental system.

The genetic rationale. The foundational observation came from knockdown work, not inhibitor work: silencing NNMT expression in adipose tissue of experimental mice was reported to change energy-metabolism readouts and body composition in diet-challenged animals, with NNMT itself found elevated in adipose tissue in obese and diabetic mouse models. This established NNMT as a target of interest before selective small-molecule inhibitors existed.

Adipocyte cell-culture data. In cultured adipocytes, NNMT inhibition was reported to raise NAD+ and SAM, lower 1-MNA, and reduce markers of lipogenesis — the cell-level readout consistent with the enzyme’s role in the SAM and NAD+ pathways.

Rodent metabolic models. In diet-induced obese mice, systemic administration of selective NNMT inhibitors of this class was reported to reduce white adipose tissue mass, adipocyte size, body weight, and plasma total cholesterol in the study window, with the published reports noting no change in total food intake and no observed adverse effects over the observation period. These are described as findings in an animal model; they are not statements about any human or veterinary use.

Aged skeletal-muscle model. A separate line of work examined NNMT in aged skeletal muscle, where the enzyme accumulates and local NAD+ declines. In aged mice, an NNMT inhibitor of this scaffold was reported to increase satellite (muscle stem) cell activity and regenerating-fiber size after induced injury, alongside improved measured contractile output relative to vehicle controls — the authors linking the effect to a restored local NAD+ environment and downstream NAD+-dependent signaling. This extends the compound’s research relevance beyond adipocyte metabolism into NAD+-economy and regenerative-biology models.

Across all of these, the interpretive constraint is the same: results are model-specific, several derive from a small number of research groups, and the absence of published human clinical trials for 5-amino-1MQ means nothing in this section transfers to human physiology. It is preclinical data about an enzyme target.

Section 4 — Published Literature (Verifiable Citations)

The following are real, published references retrievable through PubMed and PubMed Central (PMC). Researchers are encouraged to read the primary sources directly.

• Kraus D, Yang Q, Kong D, et al. “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.” Nature. 2014;508(7495):258-262 (doi:10.1038/nature13198). PubMed: 24717514; PMC4107212 — the founding target-validation paper linking adipose NNMT to energy metabolism.
• Neelakantan H, Vance V, Wetzel MD, et al. “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.” Biochemical Pharmacology. 2018;147:141-152 (doi:10.1016/j.bcp.2017.11.007) — the study identifying 5-amino-1MQ from a 1-methylquinolinium series with high membrane permeability and NNMT selectivity.
• Neelakantan H, Brightwell CR, Graber TG, et al. “Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle.” Biochemical Pharmacology. 2019;163:481-492 (doi:10.1016/j.bcp.2019.02.008). PubMed: 30753815 — NNMT inhibition and satellite-cell activity in aged mouse muscle.
• Kannt A, Rajagopal S, Kadnur SV, et al. “A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders.” Scientific Reports. 2018;8:3737 (doi:10.1038/s41598-018-22081-7). PMC5826917 — independent small-molecule NNMT inhibitor characterization in metabolic models.
• “Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice.” Scientific Reports. 2021 (PMC7952898) — NNMT inhibition studied alongside dietary intervention in a rodent model.
• “Mechanisms and inhibitors of nicotinamide N-methyltransferase.” Review (PMC8372200) — enzymology, the SAM methyl-sink concept, and the inhibitor landscape.

Citing real primary literature is a core part of the PYXAX research-context standard. Two caveats apply specifically to this literature. First, much of the inhibitor pharmacology traces to a small number of research groups, and independent replication of specific in-vivo endpoints remains limited. Second, a great deal of secondary vendor material restates the mouse metabolic findings as though they were established human outcomes — they are not. Verify each claim against a retrievable primary source rather than a secondary summary, including this one.

Section 5 — Research Applications (In-Vitro Use Cases)

Within qualified laboratory settings, 5-amino-1MQ is used as a reference and probe compound in several categories of in-vitro and preclinical work:

• NNMT enzyme-kinetics assays — as a defined substrate-competitive inhibitor for characterizing NNMT activity and inhibition constants in cell-free systems.
• NAD+ metabolism research — as a tool to perturb the nicotinamide-to-1-MNA branch and study downstream NAD+ pool dynamics in cultured cells.
• SAM / methyl-donor flux studies — as a probe for the “methyl sink” hypothesis, measuring SAM, SAH, and 1-MNA pools when NNMT is inhibited.
• Adipocyte metabolism models — as a reference compound in cultured-adipocyte lipogenesis and energy-metabolism assays.
• Regenerative and aging biology — as a probe in satellite-cell and NAD+-economy models in preclinical tissue systems.
• Methyltransferase selectivity screening — as a benchmark NNMT-selective inhibitor when counter-screening against related SAM-dependent methyltransferases.

Each application is an in-vitro or preclinical research use. Compounds supplied for research must not be used in any human or veterinary context.

Section 6 — How to Evaluate a Source

Because 5-amino-1MQ is a small charged molecule rather than a peptide, its documentation should be read with small-molecule expectations — and the salt-form question makes complete documentation more, not less, important.

Step 1 — Confirm the exact molecule and salt form. The certificate of analysis (COA) should identify the material as 5-amino-1-methylquinolinium, state the salt form explicitly (e.g., iodide), and give the corresponding molecular weight. Because the active species is a cation paired with a counter-ion, a milligram figure is only meaningful once the salt form is known.

Step 2 — Confirm the testing laboratory is named. “Third-party tested” is meaningless without a named, accredited laboratory. Look for an ISO/IEC 17025-accredited facility and a COA that names the lab that tested the specific batch.

Step 3 — Confirm identity by mass spectrometry. For a ~159 Da cation, LC-MS should show a clean cation signal consistent with C₁₀H₁₁N₂⁺, not a peptide-style multiply-charged series. A COA reporting only a purity percentage without an identity mass is incomplete.

Step 4 — Read the chromatogram for the right impurities. HPLC should show a single dominant peak. For a synthetic small molecule the impurity questions are synthetic byproducts, unreacted precursors, and residual solvents — different from the deletion-sequence concerns of a peptide. Purity without an identity method does not establish that the main peak is the intended compound.

Step 5 — Verify lot specificity and a complete panel. The batch number on the COA must match the vial label and correspond to the production lot — not a single historical test applied across an entire catalog. A COA you can verify independently, through a QR-linked laboratory portal or a searchable community database, is the standard to hold. For cell-based work, purity and identity should be accompanied by endotoxin and heavy-metal data, both of which can confound sensitive assay systems.

Section 7 — Regulatory Context (July 2026)

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 at the FDA’s White Oak campus to consider a set of peptides for potential inclusion on the Section 503A Bulk Drug Substances List, with a docket that includes BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon.

5-Amino-1MQ is not a peptide and is not on that docket. This is worth stating precisely, because absence from a review list is easily misread in both directions. It does not mean 5-amino-1MQ has been cleared, endorsed, or approved for any compounding or clinical use, and it equally does not mean the compound has been restricted. As a small-molecule NNMT inhibitor with no published human clinical trials, it exists in the research-compound category and its status is unchanged by the outcome of the July peptide review.

PCAC recommendations are advisory only and are not final until the FDA issues its own determination. This review concerns pharmacy compounding permissions; it does not constitute FDA approval of any compound as a pharmaceutical drug. Researchers remain responsible for compliance with all applicable regulations in their jurisdiction. (See the PYXAX FDA peptide reclassification and peptide-compliance landscape guides for the full picture.)

Section 8 — PYXAX Verification Standard

Every PYXAX batch is independently third-party tested by accredited laboratories including ILS Labs, Krause Analytical, and Janoshik. Batch-specific COAs are published for every lot, naming the accredited lab that tested that batch.

Testing panel:

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin (USP <85> LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number, matching the COA in the PYXAX COA Library, so researchers can confirm identity — including exact salt form and species supplied — before ordering.

Community verification. Select lots are submitted to Janoshik Analytical, with results publicly searchable by batch number — no vendor contact required. Founding batches were verified through Krause Analytical (accredited US laboratory), and ongoing production lots are tested across the accredited-laboratory network described above.

View PYXAX 5-Amino-1MQ →
View COA Library →
Read The PYXAX Standard →

Additional resources: pyxax.com/shop/ · pyxax.com/standard/

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.